In addition, F-box and WD repeat domain-containing 7 (FBW7), a pancreatic tumor suppressor inhibited by oncogenic KRAS mutation, inhibited glycolysis in pancreatic cancer cells and enhanced the efficacy of gemcitabine in xenograft models as well [151]. The gene discussed is KRAS; the disease is pancreatic neoplasm.